Levetiracetam
Product Images NDC 50090-4023

8 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-4023). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500904023)

Label Image (Lbl500904023)
Levetiracetam 1000 mg tablets label from A-S Medication Solutions. The package contains 30 tablets, each film-coated with 1000 mg of levetiracetam USP. Storage instructions specify keeping between 68 to 77 degrees Fahrenheit. Additional details include lot number, expiration date, and a QR code for dosage information.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A vertical bar chart titled "Responder Rate (≥50% Reduction from Baseline) in Study 1" showing the percentage of patients responding by treatment group. The chart compares three groups: Placebo with about 7.4% responders (N=95), Levetiracetam 1000 mg/day with about 37.1% responders (N=97), and Levetiracetam 3000 mg/day with about 39.6% responders (N=101). Bars for both Levetiracetam doses have asterisks indicating statistical significance versus placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients responding to treatment. The graph compares placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The y-axis represents the percentage of patients, and statistically significant differences versus placebo are noted with an asterisk.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients responding to Placebo (14.4%) versus Levetiracetam 3000 mg/day (39.4%). The chart indicates a statistically significant higher response rate for Levetiracetam compared to placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
Bar chart showing responder rates with at least 50% reduction from baseline in Study 4 comparing Placebo (19.6% of patients, N=97) and Levetiracetam (44.6% of patients, N=101). The Levetiracetam group shows a statistically significant higher responder rate versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
A bar chart titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5.' It compares percentages of patients responding to Placebo (19.6%, N=51) versus Levetiracetam (43.1%, N=58), with an asterisk indicating statistical significance for Levetiracetam compared to placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar chart showing the responder rate (≥50% reduction from baseline) in PGTC seizure frequency per week in Study 7, comparing placebo and Levetiracetam. The placebo group (N=84) shows a responder rate of 45.2%, while the Levetiracetam group (N=79) shows a higher responder rate of 72.2%, marked as statistically significant versus placebo.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of levetiracetam, showing its characteristic pyrrolidone ring bonded to an ethyl group and an amide functional group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.